



ASX Announcement

28 November 2023

EXPIRY OF QUOTED OPTIONS (ASX: AVEO)

Melbourne, Australia, 28 November 2023: Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or the "Company"), advises the holders of the Company's 122,443,182 quoted options (ASX: AVEO) exercisable at \$0.035 each will expire on 31 December 2023 ("Options").

Clause 5.3 of the Appendix 6A of the ASX Listing Rules provides that a listed entity is not required to send a notice to holders of quoted options that are about to expire where the options are substantially out of the money (i.e., where the closing market price for the underlying securities on the trading day is 20 business days before the expiry is less than 50% of the option exercise price and the highest market price at which the underlying securities have traded on the ASX in the 6 months preceding that trading day is less than 75% of the option exercise price).

The Company advises that option expiry notices will not be sent to the holders of the Options as the Options are substantially out of the money.

In accordance with Clause 5.2 of the Appendix 6A of the Listing Rules, the Company provides the following information:

- The number of Options to which this notice applies are 122,443,182 and for every Option exercised, the holder of the Option will be issued one fully paid ordinary share ("Share").
- The exercise price of the Options is \$0.035 each.
- The due date for the payment of the exercise of the Options is 31 December 2023 ("Expiry Date").
- If the Options are not exercised and payment for the exercise of the Options is not received by the Expiry Date, the Options will automatically lapse, and all rights attached to the Options will cease.
- The quotation of Options on the ASX will end on 21 December 2023, being four business days before the Expiry Date.
- The last closing market price of the Shares (being the underlying securities to which the Options relate) was \$0.004 on 27 November 2023.
- During the three months immediately before the date of this notice:
 - The lowest market price of the Shares was \$0.003 per Share on 2 and 15 November 2023; and
 - The highest market price of the Shares was \$0.007 per Share on 29 and 30 August, and 4 September 2023.
- The exercise of the Options is not underwritten.

For enquiries, please contact

Ms Melanie Leydin
Company Secretary
Avecho Biotechnology Limited
+61 3 9002 5000

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

About Avecho

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (**TPM®**). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.

See more here - avecho.com.au